VENUS REMEDIES
Back to Balance Sheet
|
VENUS REMEDIES Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹31 Cr | ₹30 Cr | ₹40 Cr | ₹11 Cr | ₹0.16 Cr |
What is the latest Contingent Liabilities ratio of VENUS REMEDIES ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹31 Cr |
| Mar2024 | ₹30 Cr |
| Mar2023 | ₹40 Cr |
| Mar2022 | ₹11 Cr |
| Mar2021 | ₹0.16 Cr |
How is Contingent Liabilities of VENUS REMEDIES Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹31 Cr | 0.51 | |
| Mar2024 | ₹30 Cr | -23.13 | |
| Mar2023 | ₹40 Cr | 272.42 | |
| Mar2022 | ₹11 Cr | 6,423.93 | |
| Mar2021 | ₹0.16 Cr | - | |
Compare Contingent Liabilities of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹896.1 Cr | -1.8% | -15.7% | 106.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹419,728.0 Cr | -0.8% | 7.4% | 8.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,236.0 Cr | -1.5% | 5.7% | 11.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹146,951.0 Cr | -1.8% | 8.8% | 44.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,765.0 Cr | -1.2% | 9.2% | 14.9% | Stock Analytics | |
| CIPLA | ₹106,033.0 Cr | -2.5% | 0.1% | -7.6% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | -1.8% |
-15.7% |
106.5% |
| SENSEX | -3.8% |
-2% |
6.3% |
You may also like the below Video Courses